AU - AREFI, S.H AU - KASSAIAN, E AU - MIRHAJI, P AU - ALI FEIZZADEH, K TI - THE COMPARATIVE STUDY OF ANTIHYPERTENSIVE TREATMENTS (CSAT): BACKGROUNDS, METHODS, AND THE PRELIMINARY RESULTS (INTERIM REPORT) PT - JOURNAL ARTICLE TA - MJIRI JN - MJIRI VO - 9 VI - 4 IP - 4 4099 - http://mjiri.iums.ac.ir/article-1-1641-en.html 4100 - http://mjiri.iums.ac.ir/article-1-1641-en.pdf SO - MJIRI 4 AB  - The "Comparative Study of Antihypertensive Treatments"-CSA T is a placebo-controlled, randomized, double-blind clinical trial, with the primary objective of comparing the efficacy of different pharmacological treatments of hypertension. Drug side-effects, patient compliance, and alterations in the patients' quality of life are also compared. Subjects with mild to moderate diastolic hypertension aged above 30 are randomized into either of 5 groups receiving methyldopa, atenolol, nifedipine, triamterene-H, or placebo. After a dose titration phase, the minimum drug dose required to achieve a therapeutic goal of less than 91 mmHg for diastolic blood pressure (DBP) is determined, and the patient then enters a maintenance phase of 6 months. This report presents the preliminary results of drug efficacy in 136 subjects who have completed the dose titration phase. Age, sex, baseline systolic blood pressure (SBP) and baseline DBP were all well balanced across placebo and drug groups: mean age ± SD = 51.9 ± 9.2 years sex distribution: 56.6% males: mean DBP ± SD = 98.5 ± 5.4 mmHg mean SBP ± SD = 152.1 ± 14.4 mmHg (SD = standard deviation, SBP and DBP values were measured in the sitting position). SBP and DBP reduction in the active treatment groups (mean ± SE: 17.8 ± 1.4 mmHg for SBP, 12.4±0.7 mmHg for DBP) were significantly greater than in the placebo group (mean± SE: 7.9± 1.6 mmHg for SBP, 7.23 ±0.9 mmHg forDBP) at the end of the dose titration phase (P < 0.00001). There was greater SBP reduction with atenolo1 23.9 ± 3.2 mmHg) than with either nifedipine (12.5 ± 2.3 mmHg) or triamterene-H (16.2 ± 2.7 mmHg), P CP - IRAN IN - LG - eng PB - MJIRI PG - 285 PT - Original Research YR - 1996